Phase i trial of endoxifen GEL versus placebo GEL in women undergoing breast surgery
Ended Awarded Last action
- Contract number
- HHSN26100014
- Awardee
-
Northwestern University UEI KG76WYENL5K1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $416,271
Award facts
- Contract value 86% obligated
-
- $416,271.10 Current, with exercised options
- $481,539.10 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Evanston, IL 60208, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$180,099 | |
| Funding Only Action | -$85,501 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Exercise an Option | $117,941 | |
| Exercise an Option | $88,197 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $128,664 | |
| Original award | $347,069 |
About this award
This is a federal contract award from the National Cancer Institute (NCI) to Northwestern University, a private research university, for a Phase I clinical trial to evaluate the dermal tolerability and safety of an endoxifen gel in women undergoing breast surgery. The contract, which is part of NCI's Cancer Prevention Agent Development Program, has a ceiling value of $481,539.10 and a period of performance through August 31, 2023. Northwestern University is the prime contractor, with Vanderbilt University Medical Center and Sloan-Kettering Institute for Cancer Research serving as subcontractors. This contract does not have a set-aside designation. The NCI is the funding agency, and this award supports early-phase clinical research to advance the development of cancer prevention agents.
Quick answers
Who was awarded contract HHSN26100014?
HHSN26100014 was awarded to Northwestern University by National Cancer Institute (National Institutes of Health) on September 15, 2017.
How much is contract HHSN26100014 worth?
The government has obligated $416,271 on HHSN26100014. Its potential value, with all options, is $481,539.
Is contract HHSN26100014 an order under another contract?
Yes. HHSN26100014 is a delivery order under HHSN261201200035I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100014 competed?
The extent of competition for HHSN26100014 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award